TY 2072
Alternative Names: TY-2072Latest Information Update: 17 Jun 2025
At a glance
- Originator TYK Medicine
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HER2 negative breast cancer
Most Recent Events
- 25 Apr 2025 Preclinical trials in HER2-negative-breast-cancer in China (unspecified route), before April 2025
- 25 Apr 2025 TYK Medicines plans a IND enabling studies
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)